196 related articles for article (PubMed ID: 32993581)
41. Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.
Pan CC; Chen PC; Chou TY; Chiang H
Hum Pathol; 2003 Nov; 34(11):1155-62. PubMed ID: 14652817
[TBL] [Abstract][Full Text] [Related]
42. Thymic epithelial tumors: a clinicopathologic study of 249 cases from a single institution.
Su XY; Wu WL; Liu N; Zhang SF; Li GD
Int J Clin Exp Pathol; 2014; 7(11):7760-7. PubMed ID: 25550813
[TBL] [Abstract][Full Text] [Related]
43. Flow cytometric analysis of lymphoid cells in thymic epithelial neoplasms.
Nakajima J; Takamoto S; Oka T; Tanaka M; Takeuchi E; Murakawa T
Eur J Cardiothorac Surg; 2000 Sep; 18(3):287-92. PubMed ID: 10973537
[TBL] [Abstract][Full Text] [Related]
44. The Impact of Postoperative Radiotherapy for Thymoma and Thymic Carcinoma.
Jackson MW; Palma DA; Camidge DR; Jones BL; Robin TP; Sher DJ; Koshy M; Kavanagh BD; Gaspar LE; Rusthoven CG
J Thorac Oncol; 2017 Apr; 12(4):734-744. PubMed ID: 28126540
[TBL] [Abstract][Full Text] [Related]
45. Correlation between the Expression of PD-L1 and Clinicopathological Features in Patients with Thymic Epithelial Tumors.
Chen Y; Zhang Y; Chai X; Gao J; Chen G; Zhang W; Zhang Y
Biomed Res Int; 2018; 2018():5830547. PubMed ID: 29850538
[TBL] [Abstract][Full Text] [Related]
46. p53, cellular proliferation, and apoptosis-related factors in thymic neuroendocrine tumors.
Gal AA; Sheppard MN; Nolen JD; Cohen C
Mod Pathol; 2004 Jan; 17(1):33-9. PubMed ID: 14631373
[TBL] [Abstract][Full Text] [Related]
47. Detection of bcl-2 and p53 in thymoma: expression of bcl-2 as a reliable marker of tumor aggressiveness.
Chen FF; Yan JJ; Jin YT; Su IJ
Hum Pathol; 1996 Oct; 27(10):1089-92. PubMed ID: 8892596
[TBL] [Abstract][Full Text] [Related]
48. Epidermal growth factor receptor expression in invasive thymoma.
Henley JD; Koukoulis GK; Loehrer PJ
J Cancer Res Clin Oncol; 2002 Mar; 128(3):167-70. PubMed ID: 11935304
[TBL] [Abstract][Full Text] [Related]
49. Treatment Outcome and Prognostic Factors of Malignant Thymoma - A Single Institution Experience.
Alothaimeen HS; Memon MA
Asian Pac J Cancer Prev; 2020 Mar; 21(3):653-661. PubMed ID: 32212790
[TBL] [Abstract][Full Text] [Related]
50. Immunohistochemical staining for bcl-2 and mcl-1 in intrathyroidal epithelial thymoma (ITET)/carcinoma showing thymus-like differentiation (CASTLE) and cervical thymic carcinoma.
Dorfman DM; Shahsafaei A; Miyauchi A
Mod Pathol; 1998 Oct; 11(10):989-94. PubMed ID: 9796728
[TBL] [Abstract][Full Text] [Related]
51. The distribution of epithelial membrane antigen in thymic epithelial neoplasms.
Fukai I; Masaoka A; Hashimoto T; Yamakawa Y; Mizuno T; Tanamura O
Cancer; 1992 Oct; 70(8):2077-81. PubMed ID: 1394038
[TBL] [Abstract][Full Text] [Related]
52. Protein expression and gene copy number changes of receptor tyrosine kinase in thymomas and thymic carcinomas.
Mimae T; Tsuta K; Kondo T; Nitta H; Grogan TM; Okada M; Asamura H; Tsuda H
Ann Oncol; 2012 Dec; 23(12):3129-3137. PubMed ID: 22700994
[TBL] [Abstract][Full Text] [Related]
53. [Role of Postoperative Radiotherapy for Stage I/II/III Thymic Tumor - Results of the ChART Retrospective Database].
Liu Q; Gu Z; Yang F; Fu J; Shen Y; Wei Y; Tan L; Zhang P; Han Y; Chen C; Zhang R; Li Y; Chen KN; Chen H; Liu Y; Cui Y; Wang Y; Pang L; Yu Z; Zhou X; Liu Y; Xiang J; Liu Y; Fang W;
Zhongguo Fei Ai Za Zhi; 2016 Jul; 19(7):465-72. PubMed ID: 27339724
[TBL] [Abstract][Full Text] [Related]
54. Thymic tumors: relevant molecular data in the clinic.
Girard N
J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S291-5. PubMed ID: 20859122
[TBL] [Abstract][Full Text] [Related]
55. Outcomes after surgical resection of thymic carcinoma: A study from a single tertiary referral centre.
Song Z; Zhang Y
Eur J Surg Oncol; 2014 Nov; 40(11):1523-7. PubMed ID: 24953416
[TBL] [Abstract][Full Text] [Related]
56. Tumor-node metastasis staging system for thymic epithelial tumors.
Kondo K
J Thorac Oncol; 2010 Oct; 5(10 Suppl 4):S352-6. PubMed ID: 20859132
[TBL] [Abstract][Full Text] [Related]
57. Apoptosis-related (survivin, Bcl-2), tumor suppressor gene (p53), proliferation (Ki-67), and non-receptor tyrosine kinase (Src) markers expression and correlation with clinicopathologic variables in 60 thymic neoplasms.
Khoury T; Arshad A; Bogner P; Ramnath N; Zhang S; Chandrasekhar R; Wilding G; Alrawi S; Tan D
Chest; 2009 Jul; 136(1):220-228. PubMed ID: 19318677
[TBL] [Abstract][Full Text] [Related]
58. Modified Masaoka stage and size are independent prognostic predictors in thymoma and modified Masaoka stage is superior to histopathologic classifications.
Roden AC; Yi ES; Jenkins SM; Edwards KK; Donovan JL; Cassivi SD; Marks RS; Garces YI; Aubry MC
J Thorac Oncol; 2015 Apr; 10(4):691-700. PubMed ID: 25629638
[TBL] [Abstract][Full Text] [Related]
59. Thymoma. Histologic subclassification is an independent prognostic factor.
Quintanilla-Martinez L; Wilkins EW; Choi N; Efird J; Hug E; Harris NL
Cancer; 1994 Jul; 74(2):606-17. PubMed ID: 8033040
[TBL] [Abstract][Full Text] [Related]
60. Enhanced expression of telomerase activity in thymoma and thymic carcinoma tissues: a clinicopathologic study.
Watanabe M; Yu SK; Sawafuji M; Kawamura M; Horinouchi H; Mukai M; Kobayashi K
Cancer; 2002 Jan; 94(1):240-4. PubMed ID: 11815982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
